Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Debt (2023 - 2024)

Iovance Biotherapeutics has reported Total Debt over the past 5 years, most recently at $1.0 million for Q4 2024.

  • Quarterly results put Total Debt at $1.0 million for Q4 2024, changed 0.0% from a year ago — trailing twelve months through Dec 2024 was $1.0 million (changed 0.0% YoY), and the annual figure for FY2024 was $1.0 million, changed 0.0%.
  • Total Debt for Q4 2024 was $1.0 million at Iovance Biotherapeutics, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Total Debt for IOVA hit a ceiling of $1.0 million in Q1 2023 and a floor of $1.0 million in Q1 2023.